Share Price, page-7891

I am trying to see negatives leading up to Decembers announcement. I cannot see many at all.

Some people talk about competition. The "competition" are still all "treatments" - just like us - no cures.... and not any that have such a potentially wide-ranging treatment like ours. Jon Pilcher and the Neuren team have not limited NNZ2591 to just the 4 or 5 conditions that we currently target. There are plenty more than that.

Then there is the imho - unlikely - negative result for PMS next month. I guess if that does happen - our immediate value returns to just being Daybue. That would probably see a retrace to under $10.00 in the share price. But that would once again be a buying opportunity for the faithful.
Market manipulation may be a factor again?

The promised economic gloom and doom due to rising interest rates, etc - may be a factor - however, by then companies like Neuren will possibly become a "safe haven" for peoples money.

Then there is the left field "cure for all neurological conditions" that could wipe us out... Likelihood ... 0.00000000001%.

So, positive results next month for PMS and moving that to phase 3 and on to production/market is the most likely result. Before Xmas.
Once that happens, then I believe that the real value of this wonderful science that we all own as shareholders will be reflected in the Share Price.

The potential here is huge.
GLTAH